Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 04 - 06 tags : Covid-19 save search
Shareholders Raise Questions on COVID-19 Pricing Ahead of Annual Biopharma Me...
Published: 2021-04-06 (Crawled : 19:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.4%
H: 0.27%
C: -0.42%
covid biopharma covid-19
Shareholders Raise Questions on COVID-19 Pricing Ahead of Annual Biopharma Meetings
Published: 2021-04-06 (Crawled : 19:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.4%
H: 0.27%
C: -0.42%
covid biopharma covid-19
Current COVID-19 Vaccines are Great. Can They be Better?
Published: 2021-04-06 (Crawled : 18:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.4%
H: 0.27%
C: -0.42%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.98%
H: 1.11%
C: 0.2%
covid vaccine covid-19
2021 COVID-19 News: Moderna Pays out $1 Million for Security and More
Published: 2021-04-06 (Crawled : 16:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.4%
H: 0.27%
C: -0.42%
covid security covid-19
$220.8 Million Worldwide Butylated Hydroxytoluene Industry to 2027 - Impact of COVID-19 on the Market
Published: 2021-04-06 (Crawled : 15:15) - prnewswire.com
EMN | $96.36 -0.46% 0.0% 1.1M
|
Process Industries
|
| O: 0.0%
H: 2.39%
C: 0.37%
covid covid-19
Ampio Pharmaceuticals' Study Shows Ampion Inhibits a Key Inflammatory Pathway in COVID-19 and Lupus Nephritis
Published: 2021-04-06 (Crawled : 13:35) - prnewswire.com
AMPE | $0.286 0.0% 8K
|
Health Technology
|
| O: 2.26%
H: 1.66%
C: 0.0%
covid lupus covid-19
Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial
Published: 2021-04-06 (Crawled : 13:35) - biospace.com/
IQV | $240.84 0.93% 0.0% 1.5M
|
Health Services
|
| O: -0.03%
H: 1.74%
C: 1.63%
MBRX | $4.6 3.37% 7.4K
|
Health Technology
|
| O: 1.53%
H: 0.0%
C: -3.01%
covid potential trial covid-19
Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
Published: 2021-04-06 (Crawled : 06:00) - globenewswire.com
DVAX | $11.42 -2.89% -2.98% 1.3M
|
Health Technology
|
| O: 2.13%
H: 4.49%
C: 0.7%
covid phase 1 positive vaccine vla2001 phase 3 phase 2 covid-19
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.